Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

Published:2015-05-14 Issue:1 Volume:15 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Kimura Mai,Tamura Yuichi,Takei Makoto,Yamamoto Tsunehisa,Ono Tomohiko,Fujita Jun,Kataoka Masaharu,Kuwana Masataka,Satoh Toru,Fukuda Keiichi

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/article/10.1186/s12890-015-0037-8/fulltext.html

Reference20 articles.

1. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214–21.

2. Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, Dall'ava-Santucci J, et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:1061–7.

3. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398–403.

4. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebocontrolled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149–53.

5. Galie’ N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol;CJC Open;2022-09

2. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension;BMC Pulmonary Medicine;2017-10-26

3. A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases;Biomedicine & Pharmacotherapy;2017-10

4. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension;Journal of Cardiovascular Pharmacology;2016-02

5. Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension;Current Pharmaceutical Design;2015-11-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3